Since its initial discovery in gliomas [6,7], IDH1 and IDH2 mutations have been described in a variety of other cancers including acute myeloid leukaemia, thyroid carcinomas, cartilaginous tumours such as enchondroma and chondrosarcoma, and cholangiocarcinomas. Here, IDH2 is linked to chondrosarcoma.